• Users Online: 661
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2022  |  Volume : 5  |  Issue : 1  |  Page : 192-193

Secondary cytoreductive surgery in recurrent ovarian carcinoma


Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Date of Submission10-Jan-2022
Date of Decision22-Jan-2022
Date of Acceptance23-Jan-2022
Date of Web Publication24-Feb-2022

Correspondence Address:
Ajay Gogia
Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi - 110 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/crst.crst_14_22

Rights and Permissions

How to cite this article:
Ganguly S, Gogia A. Secondary cytoreductive surgery in recurrent ovarian carcinoma. Cancer Res Stat Treat 2022;5:192-3

How to cite this URL:
Ganguly S, Gogia A. Secondary cytoreductive surgery in recurrent ovarian carcinoma. Cancer Res Stat Treat [serial online] 2022 [cited 2022 May 28];5:192-3. Available from: https://www.crstonline.com/text.asp?2022/5/1/192/342444



Harter et al.[1] recently reported an improvement in survival with secondary cytoreductive surgery in recurrent ovarian carcinoma after a platinum-free interval (PFI) of more than 6 months. We noted with interest that a majority of patients (306/401; 76.3%) had a PFI >12 months. In this subgroup, the benefit of surgery could not be conclusively demonstrated. Similarly, in the previously published GOG-0213 trial,[2] in the subgroup of patients with PFI >12 months, secondary cytoreduction was actually detrimental to overall survival. A longer PFI predicts a better response to platinum re-treatment and improved survival.[3] In patients with a longer PFI, platinum re-treatment alone is thus expected to result in acceptable survival outcomes. Both the DESKTOP III trial[1] and the SOC-1 trial,[4] which demonstrated a survival benefit from secondary cytoreduction, had rigorous objective patient selection criteria, and the benefit of surgery was restricted to only those who achieved complete cytoreduction. The marginal benefit of surgery, if any, in patients with a longer PFI may be negated by the occurrence of surgical morbidities in the real world in the absence of a uniform model of patient selection for surgery.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 2021;385:2123-31.  Back to cited text no. 1
    
2.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 2019;381:1929-39.  Back to cited text no. 2
    
3.
Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol 2013;24:937-43.  Back to cited text no. 3
    
4.
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:439-49.  Back to cited text no. 4
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed106    
    Printed4    
    Emailed0    
    PDF Downloaded8    
    Comments [Add]    

Recommend this journal